Quality Care

Cerebral is halting prescriptions such as Adderall and Xanax for current and new patients.

Authors of the study said the results raise concerns about worsening health disparities, especially when models can detect self-reported race information where human radiologists can't.

The company said the Series B brings its total raise to $45 million.

The startup also announced a new product called Clear Contracts that aims to improve the direct contracting process.

The clinical trial with Huntsville Heart Center is expected to be completed by October.

The suspension comes as the digital mental health company faces increasing pressure over its prescription practices, particularly for ADHD medications.

The AI tech can spot signs of pancreatic cancer from non-contrast CT images.

Former vice president Matthew Truebe said he was fired after raising concerns about the company's prescribing practices, alleging Cerebral aimed to prescribe stimulants to all its ADHD patients to increase retention.

It plans to develop an in-house cloud platform.

Also: Impiricus raises a $3 million seed, and health tech VC Flare Capital Partners closes its $350 million third fund.